| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.10B | 20.10B | 19.46B | 17.97B | 17.42B | 16.47B |
| Gross Profit | 12.09B | 12.11B | 11.25B | 10.15B | 10.29B | 9.93B |
| EBITDA | 4.81B | 4.85B | 4.25B | 3.37B | 3.76B | 4.35B |
| Net Income | 2.91B | 2.89B | 2.30B | 1.78B | 2.17B | 2.69B |
Balance Sheet | ||||||
| Total Assets | 17.51B | 16.05B | 16.39B | 15.73B | 15.04B | 15.92B |
| Cash, Cash Equivalents and Short-Term Investments | 1.28B | 1.10B | 966.00M | 775.00M | 832.00M | 888.00M |
| Total Debt | 8.42B | 8.51B | 9.06B | 9.27B | 7.83B | 8.21B |
| Total Liabilities | 16.27B | 15.50B | 15.44B | 14.93B | 14.07B | 14.82B |
| Stockholders Equity | 856.00M | 212.00M | 609.00M | 401.00M | 609.00M | 743.00M |
Cash Flow | ||||||
| Free Cash Flow | 3.44B | 3.55B | 3.04B | 1.86B | 2.76B | 3.31B |
| Operating Cash Flow | 4.01B | 4.11B | 3.75B | 2.56B | 3.33B | 3.72B |
| Investing Cash Flow | -794.00M | -534.00M | -742.00M | -1.60B | -592.00M | -878.00M |
| Financing Cash Flow | -3.17B | -3.39B | -2.79B | -952.00M | -2.77B | -2.82B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $340.67B | 21.28 | 31.90% | 2.84% | 1.23% | 17.97% | |
73 Outperform | $149.67B | 25.02 | 28.36% | 3.31% | -0.30% | -14.60% | |
72 Outperform | $20.70B | 27.14 | 18.59% | 1.39% | 1.45% | 42.04% | |
63 Neutral | $61.99B | 21.55 | 450.35% | 2.62% | -0.05% | 2.49% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | $33.40B | 17.05 | 136.87% | 4.81% | -10.04% | -23.41% | |
53 Neutral | $13.29B | 17.07 | 4163.16% | 4.58% | -9.35% | 123.06% |
On July 31, 2025, Colgate-Palmolive‘s Board of Directors approved a new three-year Strategic Growth and Productivity Program aimed at driving future growth and supporting its 2030 strategy. This initiative is expected to incur cumulative pre-tax charges of $200 to $300 million, with a significant portion allocated to employee-related costs and asset-related expenses. The program will impact various regions, including North America, Latin America, Europe, Asia Pacific, Africa/Eurasia, and Hill’s Pet Nutrition, with the majority of charges anticipated to be cash expenditures by December 31, 2028.
The most recent analyst rating on (CL) stock is a Hold with a $82.00 price target. To see the full list of analyst forecasts on Colgate-Palmolive stock, see the CL Stock Forecast page.